Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Future of Genomic Sciences May Be Large-Scale Sequencing

By LabMedica International staff writers
Posted on 08 Jan 2010
Scientists are gaining insights into new ways to utilize microorganisms in medicine and manufacturing through a coordinated large-scale effort to sequence the genomes of not just individual microorganisms but entire ecosystems, according to a new report that outlines recommendations for this massive effort. More...


The report, from the American Academy of Microbiology (Washington, DC, USA), is based on a colloquium convened by the Academy in September 2008. The report outlines recommendations for large-scale microbial sequencing efforts directed toward cultivated isolates and single cells, as well as a community-scale approach to characterize a set of defined ecosystems of varying complexity.

Until recently, sequencing entire microbial genomes was laborious and costly, and the decision to sequence the genome of an organism was made by researchers or funding agencies. This ad hoc approach to collecting sequence data has resulted in an unbalanced and highly biased sampling of microbial diversity. Now, due to new technologies, the cost and effort of sequencing is within reach for even the smallest labs, and the ability to sequence the genomes of a significant fraction of microbial life may be possible. Systematic genomics efforts, such as the ones outlined in the report, would considerably broaden scientists' view of biologic diversity and have significant effects on science.

"A consensus rapidly emerged during the meeting that a taxonomically driven approach to gathering microbial genome information will provide the greatest impact on our view of microbial diversity, the potential to find novel genes and proteins, and our understanding of the complexity of the microbial consortia that maintain the health of this planet,” remarked Margaret Riley, Ph.D., colloquium chair.

The report outlined a five-pronged, coordinated initiative to comprehensively describe six different microbial ecosystems, designed to illustrate all the gene diversity across genomes. In this effort, the report noted that sequencing should be complemented by other experimental data, particularly transciptomics and metabolomics data, all of which should be gathered and curated continuously.

"Systematic genomics efforts like the ones outlined in this document would significantly broaden our view of biological diversity and have major effects on science,” stated Dr. Riley.

A full copy of the report and further recommendations can be found on the Academy website given below.

Related Links:

American Academy of Microbiology
Academy report and recommendations




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.